{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T08:56:38Z","timestamp":1793955398423,"version":"4.8.0"},"reference-count":157,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T00:00:00Z","timestamp":1629763200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010712","name":"Viet Nam National University Ho Chi Minh City","doi-asserted-by":"publisher","award":["NCM2020-28-01"],"award-info":[{"award-number":["NCM2020-28-01"]}],"id":[{"id":"10.13039\/501100010712","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.biopha.2021.112117","type":"journal-article","created":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T13:42:26Z","timestamp":1630417346000},"page":"112117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":165,"special_numbering":"C","title":["Nanotechnology-based drug delivery for central nervous system disorders"],"prefix":"10.1016","volume":"143","author":[{"given":"Thuy Trang","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi Thuy","family":"Dung Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuong Kha","family":"Vo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nguyen-Minh-An","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minh Kim","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toi","family":"Van Vo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giau","family":"Van Vo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2021.112117_bib1","unstructured":"G.B.D.N. Collaborators, Global, regional, and national burden of neurological disorders, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016, Lancet Neurol 18(5) (2019) 459\u2013480."},{"issue":"2","key":"10.1016\/j.biopha.2021.112117_bib2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s13273-015-0011-9","article-title":"Gene panels and primers for next generation sequencing studies on neurodegenerative disorders","volume":"11","author":"Van Giau","year":"2015","journal-title":"Mol. Cell. Toxicol."},{"issue":"7","key":"10.1016\/j.biopha.2021.112117_bib3","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/s41401-020-0429-z","article-title":", Nanomedicine-based immunotherapy for central nervous system disorders","volume":"41","author":"Hanif","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"issue":"5","key":"10.1016\/j.biopha.2021.112117_bib4","article-title":"Recent progress of nanomedicine in the treatment of central nervous system","volume":"3","author":"Feng","year":"2020","journal-title":"Adv. Ther."},{"key":"10.1016\/j.biopha.2021.112117_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111623","article-title":"Advances in developing therapeutic strategies for Alzheimer\u2019s disease","volume":"139","author":"Nguyen","year":"2021","journal-title":"Biomed. Pharmacother."},{"issue":"4","key":"10.1016\/j.biopha.2021.112117_bib6","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2147\/NDT.S2006","article-title":"Current approaches to the treatment of Parkinson\u2019s disease","volume":"4","author":"Jankovic","year":"2008","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"5","key":"10.1016\/j.biopha.2021.112117_bib7","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3109\/09687688.2014.937468","article-title":"The blood-brain barrier: structure, function and therapeutic approaches to cross it","volume":"31","author":"Tajes","year":"2014","journal-title":"Mol. Membr. Biol."},{"issue":"4","key":"10.1016\/j.biopha.2021.112117_bib8","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1602\/neurorx.2.4.541","article-title":"Medicinal chemical properties of successful central nervous system drugs","volume":"2","author":"Pajouhesh","year":"2005","journal-title":"NeuroRx"},{"key":"10.1016\/j.biopha.2021.112117_bib9","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jns.2018.09.033","article-title":"Mitochondrial therapeutic interventions in Alzheimer\u2019s disease","volume":"395","author":"Van Giau","year":"2018","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.biopha.2021.112117_bib10","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/978-3-030-55035-6_13","article-title":"Therapeutic strategies and nano-drug delivery applications in management of aging alzheimer\u2019s disease","volume":"1286","author":"Nguyen","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"issue":"3","key":"10.1016\/j.biopha.2021.112117_bib11","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1021\/acs.nanolett.9b04683","article-title":"Charge conversional biomimetic nanocomplexes as a multifunctional platform for boosting orthotopic glioblastoma RNAi therapy","volume":"20","author":"Liu","year":"2020","journal-title":"Nano Lett."},{"issue":"7","key":"10.1016\/j.biopha.2021.112117_bib12","article-title":"Progress of cell-derived biomimetic drug delivery systems for cancer therapy","volume":"1","author":"Lang","year":"2018","journal-title":"Adv. Ther."},{"key":"10.1016\/j.biopha.2021.112117_bib13","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jconrel.2016.05.044","article-title":"Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases","volume":"235","author":"Saraiva","year":"2016","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.biopha.2021.112117_bib14","first-page":"252","article-title":"Drug delivery to the central nervous system: a review","volume":"6","author":"Misra","year":"2003","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.biopha.2021.112117_bib15","doi-asserted-by":"crossref","unstructured":"D. Gonzalez-Carter, X. Liu, T.A. Tockary, A. Dirisala, K. Toh, Y. Anraku, K. Kataoka, Targeting nanoparticles to the brain by exploiting the blood\u2013brain barrier impermeability to selectively label the brain endothelium, Proceedings of the National Academy of Sciences 117(32) (2020) 19141\u201319150.","DOI":"10.1073\/pnas.2002016117"},{"issue":"5","key":"10.1016\/j.biopha.2021.112117_bib16","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1046\/j.1471-4159.1998.70051781.x","article-title":"CNS drug design based on principles of blood-brain barrier transport","volume":"70","author":"Pardridge","year":"1998","journal-title":"J. Neurochem."},{"issue":"4","key":"10.1016\/j.biopha.2021.112117_bib17","doi-asserted-by":"crossref","first-page":"643","DOI":"10.3233\/JAD-2011-110368","article-title":"The role of the blood brain barrier in neurodegenerative disorders and their treatment","volume":"24","author":"Palmer","year":"2011","journal-title":"J. Alzheimer\u2019S. Dis."},{"issue":"1","key":"10.1016\/j.biopha.2021.112117_bib18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","article-title":"Structure and function of the blood-brain barrier","volume":"37","author":"Abbott","year":"2010","journal-title":"Neurobiol. Dis."},{"issue":"6","key":"10.1016\/j.biopha.2021.112117_bib19","first-page":"307","article-title":"Nanotechnology-novel therapeutics for CNS disorders, Nature reviews","volume":"8","author":"Srikanth","year":"2012","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.biopha.2021.112117_bib20","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1021\/acsnano.5b08045","article-title":"Mitochondria-targeting ceria nanoparticles as antioxidants for alzheimer\u2019s disease","volume":"10","author":"Kwon","year":"2016","journal-title":"ACS nano"},{"issue":"1","key":"10.1016\/j.biopha.2021.112117_bib21","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1080\/10717544.2020.1745328","article-title":"Neuronal mitochondria-targeted therapy for Alzheimer\u2019s disease by systemic delivery of resveratrol using dual-modified novel biomimetic nanosystems","volume":"27","author":"Han","year":"2020","journal-title":"Drug Deliv."},{"key":"10.1016\/j.biopha.2021.112117_bib22","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.biopha.2018.12.133","article-title":"Applications of nanotechnology in drug delivery to the central nervous system","volume":"111","author":"Saeedi","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2021.112117_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119491","article-title":"Nanomaterial-based blood-brain-barrier (BBB) crossing strategies","volume":"224","author":"Xie","year":"2019","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.biopha.2021.112117_bib24","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ijpharm.2009.06.019","article-title":"Nanoparticles for direct nose-to-brain delivery of drugs","volume":"379","author":"Mistry","year":"2009","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.biopha.2021.112117_bib25","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2174\/1570159X11311020006","article-title":"Cell-penetrating Peptide-mediated therapeutic molecule delivery into the central nervous system","volume":"11","author":"Zou","year":"2013","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.biopha.2021.112117_bib26","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.actbio.2015.11.029","article-title":"Cell penetrating peptide-modified poly(lactic-co-glycolic acid) nanoparticles with enhanced cell internalization","volume":"30","author":"Steinbach","year":"2016","journal-title":"Acta Biomater."},{"key":"10.1016\/j.biopha.2021.112117_bib27","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jconrel.2017.12.015","article-title":"Crossing the blood-brain barrier with nanoparticles","volume":"270","author":"Zhou","year":"2018","journal-title":"J. Control. Release"},{"issue":"1\u20132","key":"10.1016\/j.biopha.2021.112117_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-5173(02)00543-4","article-title":"BCNU-loaded poly(D, L-lactide-co-glycolide) wafer and antitumor activity against XF-498 human CNS tumor cells in vitro","volume":"251","author":"Seong","year":"2003","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2021.112117_bib29","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.2147\/IJN.S61288","article-title":"Current approaches to enhance CNS delivery of drugs across the brain barriers","volume":"9","author":"Lu","year":"2014","journal-title":"Int J. Nanomed."},{"issue":"1","key":"10.1016\/j.biopha.2021.112117_bib30","first-page":"56","volume":"351","author":"Cummings","year":"2004","journal-title":"J. Med."},{"issue":"17","key":"10.1016\/j.biopha.2021.112117_bib31","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1002\/anie.200802808","article-title":"Alzheimer\u2019s disease: from pathology to therapeutic approaches","volume":"48","author":"Jakob-Roetne","year":"2009","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.biopha.2021.112117_bib32","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s11064-020-03031-0","article-title":"Role of insulin resistance in the alzheimer\u2019s disease progression","volume":"45","author":"Nguyen","year":"2020","journal-title":"Neurochem. Res."},{"issue":"9","key":"10.1016\/j.biopha.2021.112117_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21093165","article-title":"Type 3 Diabetes and Its Role Implications in Alzheimer\u2019s Disease","volume":"21","author":"Nguyen","year":"2020","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2021.112117_bib34","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jns.2017.03.031","article-title":"Role of inflammatory molecules in the Alzheimer\u2019s disease progression and diagnosis","volume":"376","author":"Bagyinszky","year":"2017","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2021.112117_bib35","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006189","article-title":"Neuropathological alterations in Alzheimer disease","volume":"1","author":"Serrano-Pozo","year":"2011","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"9","key":"10.1016\/j.biopha.2021.112117_bib36","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1038\/s41380-020-0762-0","article-title":"Amyloidogenic processing of Alzheimer\u2019s disease \u03b2-amyloid precursor protein induces cellular iron retention","volume":"25","author":"Tsatsanis","year":"2020","journal-title":"Mol. Psychiatry"},{"issue":"5","key":"10.1016\/j.biopha.2021.112117_bib37","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.neuron.2018.07.039","article-title":"Tau protein disrupts nucleocytoplasmic transport in alzheimer\u2019s disease","volume":"99","author":"Eftekharzadeh","year":"2018","journal-title":"Neuron"},{"key":"10.1016\/j.biopha.2021.112117_bib38","first-page":"1057","article-title":"Recent advances in PEG-PLA block copolymer nanoparticles","volume":"5","author":"Xiao","year":"2010","journal-title":"Int. J. Nanomed."},{"issue":"6","key":"10.1016\/j.biopha.2021.112117_bib39","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1021\/bc400055h","article-title":"B6 peptide-modified PEG-PLA nanoparticles for enhanced brain delivery of neuroprotective peptide","volume":"24","author":"Liu","year":"2013","journal-title":"Bioconjugate Chem."},{"issue":"6","key":"10.1016\/j.biopha.2021.112117_bib40","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.biomaterials.2010.10.027","article-title":"Curcumin-decorated nanoliposomes with very high affinity for amyloid-\u03b21-42 peptide","volume":"32","author":"Mourtas","year":"2011","journal-title":"Biomaterials"},{"issue":"25","key":"10.1016\/j.biopha.2021.112117_bib41","doi-asserted-by":"crossref","first-page":"6519","DOI":"10.1016\/j.biomaterials.2010.04.044","article-title":"Lipid-based nanoparticles with high binding affinity for amyloid-beta1-42 peptide","volume":"31","author":"Gobbi","year":"2010","journal-title":"Biomaterials"},{"issue":"8","key":"10.1016\/j.biopha.2021.112117_bib42","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.bbamem.2007.02.009","article-title":"Physicochemical interactions of amyloid beta-peptide with lipid bilayers","volume":"1768","author":"Matsuzaki","year":"2007","journal-title":"Biochim. Et. Biophys. Acta"},{"issue":"11","key":"10.1016\/j.biopha.2021.112117_bib43","doi-asserted-by":"crossref","first-page":"572","DOI":"10.3390\/pharmaceutics11110572","article-title":"Nanomedicine against A\u03b2 aggregation by \u03b2-sheet breaker peptide delivery: in vitro evidence","volume":"11","author":"Pederzoli","year":"2019","journal-title":"Pharmaceutics"},{"issue":"18","key":"10.1016\/j.biopha.2021.112117_bib44","doi-asserted-by":"crossref","first-page":"7131","DOI":"10.1002\/anie.202002028","article-title":"Light-induced chiral iron copper selenide nanoparticles prevent \u03b2-amyloidopathy in vivo","volume":"59","author":"Zhang","year":"2020","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.biopha.2021.112117_bib45","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.nano.2019.02.004","article-title":"Vitamin D-binding protein-loaded PLGA nanoparticles suppress Alzheimer\u2019s disease-related pathology in 5XFAD mice","volume":"17","author":"Jeon","year":"2019","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.biopha.2021.112117_bib46","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.nlm.2013.08.001","article-title":"Free and nanoencapsulated curcumin suppress \u03b2-amyloid-induced cognitive impairments in rats: involvement of BDNF and Akt\/GSK-3\u03b2 signaling pathway","volume":"106","author":"Hoppe","year":"2013","journal-title":"Neurobiol. Learn. Mem."},{"key":"10.1016\/j.biopha.2021.112117_bib47","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jphotobiol.2018.11.008","article-title":"A novel synthesis of selenium nanoparticles encapsulated PLGA nanospheres with curcumin molecules for the inhibition of amyloid \u03b2 aggregation in Alzheimer\u2019s disease","volume":"190","author":"Huo","year":"2019","journal-title":"J. Photochem. Photobiol. B Biol."},{"issue":"2","key":"10.1016\/j.biopha.2021.112117_bib48","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.nano.2017.12.006","article-title":"Antibody-functionalized polymer nanoparticle leading to memory recovery in Alzheimer\u2019s disease-like transgenic mouse model","volume":"14","author":"Carradori","year":"2018","journal-title":"Nanomed. Nanotechnol., Biol., Med."},{"key":"10.1016\/j.biopha.2021.112117_bib49","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.biomaterials.2019.01.037","article-title":"Sustained release of bioactive hydrogen by Pd hydride nanoparticles overcomes Alzheimer\u2019s disease","volume":"197","author":"Zhang","year":"2019","journal-title":"Biomaterials"},{"issue":"2","key":"10.1016\/j.biopha.2021.112117_bib50","first-page":"829","article-title":"Gold-nanoparticle-based multifunctional amyloid-\u03b2 inhibitor against Alzheimer\u2019s disease","volume":"21","author":"Gao","year":"2015","journal-title":"Chem. (Weinh. der Bergstr., Ger.)"},{"issue":"1","key":"10.1016\/j.biopha.2021.112117_bib51","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3233\/JAD-140321","article-title":"Is amyloid-\u03b2 an innocent bystander and marker in Alzheimer\u2019s disease? Is the liability of multivalent cation homeostasis and its influence on amyloid-\u03b2 function the real mechanism?","volume":"42","author":"ManafiRad","year":"2014","journal-title":"J. Alzheimer\u2019S. Dis."},{"key":"10.1016\/j.biopha.2021.112117_bib52","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/978-0-387-46401-5_8","article-title":"Neuroprotective effects of curcumin","volume":"595","author":"Cole","year":"2007","journal-title":"Adv. Exp. Med. Biol."},{"issue":"20","key":"10.1016\/j.biopha.2021.112117_bib53","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.1016\/j.bmcl.2016.08.092","article-title":"Design and synthesis of curcumin derivatives as tau and amyloid \u03b2 dual aggregation inhibitors","volume":"26","author":"Okuda","year":"2016","journal-title":"Bioorg. Med Chem. Lett."},{"issue":"1","key":"10.1016\/j.biopha.2021.112117_bib54","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12951-020-00626-1","article-title":"Neuron tau-targeting biomimetic nanoparticles for curcumin delivery to delay progression of Alzheimer\u2019s disease","volume":"18","author":"Gao","year":"2020","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.biopha.2021.112117_bib55","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jphotobiol.2019.01.012","article-title":"Microtubule network as a potential candidate for targeting by gold nanoparticle-assisted photothermal therapy","volume":"192","author":"Ghalandari","year":"2019","journal-title":"J. Photochem. Photobiol. B: Biol."},{"issue":"7","key":"10.1016\/j.biopha.2021.112117_bib56","doi-asserted-by":"crossref","first-page":"12833","DOI":"10.1021\/acsomega.9b01411","article-title":"Protein-capped metal nanoparticles inhibit tau aggregation in alzheimer\u2019s disease","volume":"4","author":"Sonawane","year":"2019","journal-title":"ACS Omega"},{"key":"10.1016\/j.biopha.2021.112117_bib57","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.neuroimage.2019.05.044","article-title":"Cholinergic and serotonergic modulation of resting state functional brain connectivity in Alzheimer\u2019s disease","volume":"199","author":"Klaassens","year":"2019","journal-title":"NeuroImage"},{"issue":"7","key":"10.1016\/j.biopha.2021.112117_bib58","doi-asserted-by":"crossref","first-page":"775","DOI":"10.3109\/03639045.2010.541262","article-title":"New perspective for the treatment of Alzheimer diseases: liposomal rivastigmine formulations","volume":"37","author":"Mutlu","year":"2011","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.biopha.2021.112117_bib59","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jconrel.2019.01.008","article-title":"Reassembly of native components with donepezil to execute dual-missions in Alzheimer\u2019s disease therapy","volume":"296","author":"Zhang","year":"2019","journal-title":"J. Control. Release: Off. J. Control. Release Soc."},{"key":"10.1016\/j.biopha.2021.112117_bib60","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jconrel.2019.03.010","article-title":"Dual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)\/Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe\/PS1dE9 Alzheimer\u2019s disease mice model","volume":"301","author":"Cano","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2021.112117_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchemneu.2020.101795","article-title":"Neuroprotective effect of quercetin nanoparticles: a possible prophylactic and therapeutic role in alzheimer\u2019s disease","volume":"107","author":"Rifaai","year":"2020","journal-title":"J. Chem. Neuroanat."},{"issue":"1","key":"10.1016\/j.biopha.2021.112117_bib62","doi-asserted-by":"crossref","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.biopha.2021.112117_bib63","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/bs.pbr.2019.03.004","article-title":"Nanodelivery of therapeutic agents in Parkinson\u2019s disease","volume":"245","author":"Lafuente","year":"2019","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.biopha.2021.112117_bib64","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jconrel.2018.12.036","article-title":"Micro- and nanotechnology approaches to improve Parkinson\u2019s disease therapy","volume":"295","author":"Torres-Ortega","year":"2019","journal-title":"J. Control. Release: Off. J. Control. Release Soc."},{"key":"10.1016\/j.biopha.2021.112117_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2020.129698","article-title":"Nanomaterials for parkinson disease: recent progress","volume":"1231","author":"Ghazy","year":"2021","journal-title":"J. Mol. Struct."},{"issue":"1\u20132","key":"10.1016\/j.biopha.2021.112117_bib66","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ijpharm.2009.08.021","article-title":"Design, biometric simulation and optimization of a nano-enabled scaffold device for enhanced delivery of dopamine to the brain","volume":"382","author":"Pillay","year":"2009","journal-title":"Int. J. Pharm."},{"issue":"sup1","key":"10.1016\/j.biopha.2021.112117_bib67","first-page":"434","article-title":"Nanocarrier for levodopa parkinson therapeutic drug; comprehensive benserazide analysis, artificial cells","volume":"46","author":"Yoosefian","year":"2018","journal-title":"Nanomed., Biotechnol."},{"issue":"46","key":"10.1016\/j.biopha.2021.112117_bib68","doi-asserted-by":"crossref","first-page":"39557","DOI":"10.1021\/acsami.8b17224","article-title":"PEGylated PLGA nanoparticles as a smart carrier to increase the cellular uptake of a coumarin-based monoamine oxidase B inhibitor","volume":"10","author":"Fernandes","year":"2018","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"n\/a","key":"10.1016\/j.biopha.2021.112117_bib69","first-page":"809","article-title":"Reversible photothermal modulation of electrical activity of excitable cells using polydopamine nanoparticles","volume":"n\/a","author":"Gholami Derami","year":"2008","journal-title":"Adv. Mater."},{"issue":"1","key":"10.1016\/j.biopha.2021.112117_bib70","doi-asserted-by":"crossref","first-page":"15185","DOI":"10.1038\/s41598-021-94175-8","article-title":"Dopamine-loaded nanoparticle systems circumvent the blood-brain barrier restoring motor function in mouse model for Parkinson\u2019s Disease","volume":"11","author":"Monge-Fuentes","year":"2021","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.biopha.2021.112117_bib71","doi-asserted-by":"crossref","DOI":"10.3390\/cells8060565","article-title":"Autophagy in synucleinopathy: the overwhelmed and defective machinery","volume":"8","author":"Arotcarena","year":"2019","journal-title":"Cells"},{"issue":"9","key":"10.1016\/j.biopha.2021.112117_bib72","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nrd2614","article-title":"Nanoparticle therapeutics: an emerging treatment modality for cancer","volume":"7","author":"Davis","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"issue":"23","key":"10.1016\/j.biopha.2021.112117_bib73","doi-asserted-by":"crossref","first-page":"5625","DOI":"10.3390\/molecules25235625","article-title":"Alpha-synuclein\u2014nanoparticle interactions: understanding, controlling and exploiting conformational plasticity","volume":"25","author":"D\u2019Onofrio","year":"2020","journal-title":"Molecules"},{"issue":"19","key":"10.1016\/j.biopha.2021.112117_bib74","doi-asserted-by":"crossref","first-page":"5469","DOI":"10.7150\/thno.28295","article-title":"\u201cCell-addictive\u201d dual-target traceable nanodrug for Parkinson\u2019s disease treatment via flotillins pathway","volume":"8","author":"Li","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.biopha.2021.112117_bib75","doi-asserted-by":"crossref","first-page":"8433","DOI":"10.2147\/IJN.S223182","article-title":"Vitamin K1 as a potential molecule for reducing single-walled carbon nanotubes-stimulated \u03b1-synuclein structural changes and cytotoxicity","volume":"14","author":"Naskhi","year":"2019","journal-title":"Int J. Nanomed."},{"key":"10.1016\/j.biopha.2021.112117_bib76","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3389\/fbioe.2020.00112","article-title":"Antioxidant nanoparticles for concerted inhibition of \u03b1-synuclein fibrillization, and attenuation of microglial intracellular aggregation and activation","volume":"8","author":"Zhao","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"2","key":"10.1016\/j.biopha.2021.112117_bib77","doi-asserted-by":"crossref","first-page":"344","DOI":"10.7150\/thno.16562","article-title":"Inhibition by multifunctional magnetic nanoparticles loaded with alpha-synuclein rnai plasmid in a parkinson\u2019s disease model","volume":"7","author":"Niu","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.biopha.2021.112117_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.molliq.2020.115051","article-title":"Copper oxide nanoparticles promote \u03b1-synuclein oligomerization and underlying neurotoxicity as a model of Parkinson\u2019s disease","volume":"323","author":"Lyu","year":"2021","journal-title":"J. Mol. Liq."},{"issue":"2","key":"10.1016\/j.biopha.2021.112117_bib79","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3390\/nano10020235","article-title":"Cerium oxide nanoparticles rescue \u03b1-synuclein-induced toxicity in a yeast model of parkinson\u2019s disease","volume":"10","author":"Ruotolo","year":"2020","journal-title":"Nanomater. (Basel, Switz.)"},{"issue":"Pt A","key":"10.1016\/j.biopha.2021.112117_bib80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2015.09.020","article-title":"Treatment of stroke with liposomal neuroprotective agents under cerebral ischemia conditions","volume":"97","author":"Fukuta","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"2","key":"10.1016\/j.biopha.2021.112117_bib81","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/fcp.12244","article-title":"Nanoliposome containing cyclosporine A reduced neuroinflammation responses and improved neurological activities in cerebral ischemia\/reperfusion in rat","volume":"31","author":"Partoazar","year":"2017","journal-title":"Fundam. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2021.112117_bib82","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12951-019-0442-x","article-title":"Integration of phospholipid-complex nanocarrier assembly with endogenous N-oleoylethanolamine for efficient stroke therapy","volume":"17","author":"Yang","year":"2019","journal-title":"J. Nanobiotechnol."},{"issue":"34","key":"10.1016\/j.biopha.2021.112117_bib83","doi-asserted-by":"crossref","first-page":"9128","DOI":"10.1016\/j.biomaterials.2010.08.038","article-title":"Therapeutic effects of a reducible poly (oligo-D-arginine) carrier with the heme oxygenase-1 gene in the treatment of hypoxic-ischemic brain injury","volume":"31","author":"Hyun","year":"2010","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.biopha.2021.112117_bib84","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s11596-018-1858-5","article-title":"Combination therapy with lxw7 and ceria nanoparticles protects against acute cerebral ischemia\/reperfusion injury in rats","volume":"38","author":"Zhang","year":"2018","journal-title":"Curr. Med. Sci."},{"issue":"30","key":"10.1016\/j.biopha.2021.112117_bib85","doi-asserted-by":"crossref","first-page":"9408","DOI":"10.1002\/anie.201805052","article-title":"Ceria nanoparticle systems for selective scavenging of mitochondrial, intracellular, and extracellular reactive oxygen species in parkinson\u2019s disease","volume":"57","author":"Kwon","year":"2018","journal-title":"Angew. Chem. Int. Ed."},{"issue":"2","key":"10.1016\/j.biopha.2021.112117_bib86","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/17425247.2018.1384464","article-title":"Tissue plasminogen activator-based nanothrombolysis for ischemic stroke","volume":"15","author":"Liu","year":"2018","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.biopha.2021.112117_bib87","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jconrel.2013.12.036","article-title":"Bio-responsive delivery of tissue plasminogen activator for localized thrombolysis","volume":"177","author":"Absar","year":"2014","journal-title":"J. Control. Release"},{"issue":"12","key":"10.1016\/j.biopha.2021.112117_bib88","doi-asserted-by":"crossref","first-page":"12224","DOI":"10.1021\/acsnano.8b06021","article-title":"Erythrocyte-inspired discoidal polymeric nanoconstructs carrying tissue plasminogen activator for the enhanced lysis of blood clots","volume":"12","author":"Colasuonno","year":"2018","journal-title":"ACS nano"},{"issue":"3","key":"10.1016\/j.biopha.2021.112117_bib89","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1021\/bc060322d","article-title":"Synthesis, characterization, and in vitro activity of dendrimer-streptokinase conjugates","volume":"18","author":"Wang","year":"2007","journal-title":"Bioconjugate Chem."},{"issue":"6","key":"10.1016\/j.biopha.2021.112117_bib90","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1182\/blood.V71.6.1641.1641","article-title":"Preparation of polyethylene glycol-tissue plasminogen activator adducts that retain functional activity: characteristics and behavior in three animal species","volume":"71","author":"Berger","year":"1988","journal-title":"Blood"},{"issue":"Suppl 2(Suppl 2)","key":"10.1016\/j.biopha.2021.112117_bib91","first-page":"ii1","article-title":"CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010","volume":"15","author":"Ostrom","year":"2013","journal-title":"Neuro-Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2021.112117_bib92","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","article-title":"The 2007 WHO classification of tumours of the central nervous system","volume":"114","author":"Louis","year":"2007","journal-title":"Acta Neuropathol."},{"issue":"29","key":"10.1016\/j.biopha.2021.112117_bib93","doi-asserted-by":"crossref","first-page":"11751","DOI":"10.1073\/pnas.1304504110","article-title":"Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma","volume":"110","author":"Zhou","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"22","key":"10.1016\/j.biopha.2021.112117_bib94","first-page":"8058","article-title":"In situ expression of interleukin-4 (IL-4) receptors in human brain tumors and cytotoxicity of a recombinant IL-4 cytotoxin in primary glioblastoma cell cultures","volume":"61","author":"Joshi","year":"2001","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.biopha.2021.112117_bib95","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/ijc.2910580421","article-title":"Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL4-Pseudomonas exotoxin chimeric protein","volume":"58","author":"Puri","year":"1994","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2021.112117_bib96","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1158\/1535-7163.MCT-08-0853","article-title":"Efficacy of interleukin-13 receptor-targeted liposomal doxorubicin in the intracranial brain tumor model","volume":"8","author":"Madhankumar","year":"2009","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.biopha.2021.112117_bib97","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jconrel.2012.02.023","article-title":"Focused ultrasound and interleukin-4 receptor-targeted liposomal doxorubicin for enhanced targeted drug delivery and antitumor effect in glioblastoma multiforme","volume":"160","author":"Yang","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2021.112117_bib98","doi-asserted-by":"crossref","first-page":"6673","DOI":"10.2147\/IJN.S257459","article-title":"Transferrin receptor-targeted PEG-PLA polymeric micelles for chemotherapy against glioblastoma multiforme","volume":"15","author":"Sun","year":"2020","journal-title":"Int J. Nanomed."},{"key":"10.1016\/j.biopha.2021.112117_bib99","article-title":"Enhanced delivery of therapeutic sirna into glioblastoma cells using dendrimer-entrapped gold nanoparticles conjugated with \u03b2-cyclodextrin","volume":"8","author":"Qiu","year":"2018"},{"key":"10.1016\/j.biopha.2021.112117_bib100","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ejps.2018.07.020","article-title":"Surface functionalized dendrimers as controlled-release delivery nanosystems for tumor targeting","volume":"122","author":"Ghaffari","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2021.112117_bib101","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.actbio.2017.03.055","article-title":"Protein-gold nanoparticle interactions and their possible impact on biomedical applications","volume":"55","author":"Liu","year":"2017","journal-title":"Acta Biomater."},{"issue":"5","key":"10.1016\/j.biopha.2021.112117_bib102","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.drudis.2017.11.010","article-title":"Personalized nanomedicine for CNS diseases","volume":"23","author":"Kaushik","year":"2018","journal-title":"Drug Discov. Today"},{"issue":"5","key":"10.1016\/j.biopha.2021.112117_bib103","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.biomaterials.2009.09.104","article-title":"Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain","volume":"31","author":"Wang","year":"2010","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.biopha.2021.112117_bib104","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1080\/10717544.2018.1494226","article-title":"Nose-to-brain delivery of temozolomide-loaded PLGA nanoparticles functionalized with anti-EPHA3 for glioblastoma targeting","volume":"25","author":"Chu","year":"2018","journal-title":"Drug Deliv."},{"issue":"1","key":"10.1016\/j.biopha.2021.112117_bib105","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12951-018-0356-z","article-title":"Memantine loaded PLGA PEGylated nanoparticles for Alzheimer\u2019s disease: in vitro and in vivo characterization","volume":"16","author":"Sanchez-Lopez","year":"2018","journal-title":"J. Nanobiotechnol."},{"issue":"3 Pt B","key":"10.1016\/j.biopha.2021.112117_bib106","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.ejpb.2013.03.034","article-title":"In vivo administration of VEGF- and GDNF-releasing biodegradable polymeric microspheres in a severe lesion model of Parkinson\u2019s disease","volume":"85","author":"Herr\u00e1n","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"23","key":"10.1016\/j.biopha.2021.112117_bib107","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.2174\/1381612822666160928145346","article-title":"Efficacy of ropinirole-loaded PLGA microspheres for the reversion of rotenone- induced parkinsonism","volume":"23","author":"Negro","year":"2017","journal-title":"Curr. Pharm. Des."},{"issue":"5","key":"10.1016\/j.biopha.2021.112117_bib108","first-page":"289","article-title":"The effect of poly(lactic-co-glycolic acid) (PLGA) coating on the mechanical, biodegradable, bioactive properties and drug release of porous calcium silicate scaffolds","volume":"22","author":"Zhao","year":"2012","journal-title":"Biomed. Mater. Eng."},{"key":"10.1016\/j.biopha.2021.112117_bib109","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.colsurfb.2016.04.041","article-title":"Cellular uptake of PLGA nanoparticles targeted with anti-amyloid and anti-transferrin receptor antibodies for Alzheimer\u2019s disease treatment","volume":"145","author":"Loureiro","year":"2016","journal-title":"Colloids Surf. B Biointerfaces"},{"issue":"4","key":"10.1016\/j.biopha.2021.112117_bib110","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.nano.2018.01.020","article-title":"Neuroprotective effect of gold nanoparticles composites in Parkinson\u2019s disease model","volume":"14","author":"Hu","year":"2018","journal-title":"Nanomed.: Nanotechnol., Biol., Med."},{"issue":"12","key":"10.1016\/j.biopha.2021.112117_bib111","doi-asserted-by":"crossref","first-page":"10053","DOI":"10.1166\/jnn.2015.11689","article-title":"Gold, silver and carbon nanoparticles grafted on activated polymers for biomedical applications","volume":"15","author":"Reznickova","year":"2015","journal-title":"J. Nanosci. Nanotechnol."},{"key":"10.1016\/j.biopha.2021.112117_bib112","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.actbio.2016.09.010","article-title":"Gold nanoparticle-capped mesoporous silica-based H(2)O(2)-responsive controlled release system for Alzheimer\u2019s disease treatment","volume":"46","author":"Yang","year":"2016","journal-title":"Acta Biomater."},{"issue":"5","key":"10.1016\/j.biopha.2021.112117_bib113","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1289\/ehp.0901534","article-title":"Silica-based nanoparticle uptake and cellular response by primary microglia","volume":"118","author":"Choi","year":"2010","journal-title":"Environ. Health Perspect."},{"issue":"4","key":"10.1016\/j.biopha.2021.112117_bib114","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1080\/03639045.2016.1275668","article-title":"Mesoporous silica nanoparticles for efficient rivastigmine hydrogen tartrate delivery into SY5Y cells","volume":"43","author":"Karimzadeh","year":"2017","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"6","key":"10.1016\/j.biopha.2021.112117_bib115","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1039\/C5NR08139D","article-title":"Highly selective luminescent nanostructures for mitochondrial imaging and targeting","volume":"8","author":"Fanizza","year":"2016","journal-title":"Nanoscale"},{"key":"10.1016\/j.biopha.2021.112117_bib116","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.neuint.2017.02.012","article-title":"Multifunctional liposomes interact with Abeta in human biological fluids: Therapeutic implications for Alzheimer\u2019s disease","volume":"108","author":"Conti","year":"2017","journal-title":"Neurochem Int"},{"issue":"7","key":"10.1016\/j.biopha.2021.112117_bib117","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/jps.23994","article-title":"Enhanced doxorubicin delivery to the brain administered through glutathione PEGylated liposomal doxorubicin (2B3-101) as compared with generic Caelyx,(\u00ae)\/Doxil(\u00ae)--a cerebral open flow microperfusion pilot study","volume":"103","author":"Birngruber","year":"2014","journal-title":"J. Pharm. Sci."},{"issue":"23","key":"10.1016\/j.biopha.2021.112117_bib118","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.1016\/j.biomaterials.2011.04.020","article-title":"The binding affinity of anti-A\u03b21-42 MAb-decorated nanoliposomes to A\u03b21-42 peptides in vitro and to amyloid deposits in post-mortem tissue","volume":"32","author":"Canovi","year":"2011","journal-title":"Biomaterials"},{"issue":"21","key":"10.1016\/j.biopha.2021.112117_bib119","doi-asserted-by":"crossref","first-page":"4152","DOI":"10.2174\/0929867328666201218121728","article-title":"Recent advancements in liposome-based strategies for effective drug delivery to the brain","volume":"28","author":"Zamani","year":"2021","journal-title":"Curr. Med. Chem."},{"issue":"12","key":"10.1016\/j.biopha.2021.112117_bib120","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/s41565-018-0273-1","article-title":"Roadmap and strategy for overcoming infusion reactions to nanomedicines","volume":"13","author":"Szebeni","year":"2018","journal-title":"Nat. Nanotechnol."},{"issue":"5","key":"10.1016\/j.biopha.2021.112117_bib121","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/clpt.2008.276","article-title":"Nanomedicine and society","volume":"85","author":"Ferrari","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.biopha.2021.112117_bib122","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/nnano.2008.114","article-title":"Seven challenges for nanomedicine","volume":"3","author":"Sanhai","year":"2008","journal-title":"Nat. Nanotechnol."},{"issue":"5","key":"10.1016\/j.biopha.2021.112117_bib123","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2217\/17435889.3.5.605","article-title":"Environmental challenges for nanomedicine","volume":"3","author":"Baun","year":"2008","journal-title":"Nanomed. (Lond., Engl. )"},{"issue":"7","key":"10.1016\/j.biopha.2021.112117_bib124","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1080\/17425247.2016.1244187","article-title":"Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures","volume":"14","author":"Ragelle","year":"2017","journal-title":"Expert Opin. Drug Deliv."},{"issue":"11","key":"10.1016\/j.biopha.2021.112117_bib125","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1007\/s11095-017-2240-1","article-title":"Long acting ionically paired embonate based nanocrystals of donepezil for the treatment of alzheimer\u2019s disease: a proof of concept study","volume":"34","author":"Mittapelly","year":"2017","journal-title":"Pharm. Res."},{"issue":"Pt 1","key":"10.1016\/j.biopha.2021.112117_bib126","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ijbiomac.2017.07.021","article-title":"Chitosan nanofilm and electrospun nanofiber for quick drug release in the treatment of Alzheimer\u2019s disease: in vitro and in vivo evaluation","volume":"105","author":"AnjiReddy","year":"2017","journal-title":"Int. J. Biol. Macromol."},{"issue":"2","key":"10.1016\/j.biopha.2021.112117_bib127","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3109\/03639045.2012.758130","article-title":"Preparation, characterization, in vivo biodistribution and pharmacokinetic studies of donepezil-loaded PLGA nanoparticles for brain targeting","volume":"40","author":"Md","year":"2014","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"9","key":"10.1016\/j.biopha.2021.112117_bib128","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1021\/acschemneuro.9b00343","article-title":"Design and biological evaluation of lipoprotein-based donepezil nanocarrier for enhanced brain uptake through oral delivery","volume":"10","author":"Krishna","year":"2019","journal-title":"ACS Chem. Neurosci."},{"issue":"3","key":"10.1016\/j.biopha.2021.112117_bib129","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1166\/jbn.2014.1719","article-title":"Novel L-lactide-depsipeptide polymeric carrier for enhanced brain uptake of rivastigmine in treatment of Alzheimer\u2019s disease","volume":"10","author":"Pagar","year":"2014","journal-title":"J. Biomed. Nanotechnol."},{"issue":"1","key":"10.1016\/j.biopha.2021.112117_bib130","first-page":"6","article-title":"Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting","volume":"47","author":"Fazil","year":"2012","journal-title":"Eur. J. Pharm. Sci. Off. J. Eur. Fed. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.biopha.2021.112117_bib131","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1021\/acschemneuro.9b00691","article-title":"Preparation, optimization, and evaluation of methoxy poly(ethylene glycol)-co-poly(\u03b5-caprolactone) nanoparticles loaded by rivastigmine for brain delivery","volume":"11","author":"Mohamadpour","year":"2020","journal-title":"ACS Chem. Neurosci."},{"issue":"1","key":"10.1016\/j.biopha.2021.112117_bib132","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2174\/1567201815666181004094707","article-title":"Nose to brain delivery of galantamine loaded nanoparticles: in-vivo pharmacodynamic and biochemical study in mice","volume":"16","author":"Sunena","year":"2019","journal-title":"Curr. Drug Deliv."},{"issue":"7","key":"10.1016\/j.biopha.2021.112117_bib133","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2217\/rme-2016-0032","article-title":"Effect of mesenchymal stem cells and galantamine nanoparticles in rat model of Alzheimer\u2019s disease","volume":"11","author":"Misra","year":"2016","journal-title":"Regen. Med."},{"issue":"8","key":"10.1016\/j.biopha.2021.112117_bib134","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.3109\/10717544.2016.1153748","article-title":"Pharmacological, toxicological and neuronal localization assessment of galantamine\/chitosan complex nanoparticles in rats: future potential contribution in Alzheimer\u2019s disease management","volume":"23","author":"Hanafy","year":"2016","journal-title":"Drug Deliv."},{"issue":"2","key":"10.1016\/j.biopha.2021.112117_bib135","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jconrel.2010.11.013","article-title":"Development and evaluation of polymer nanoparticles for oral delivery of estradiol to rat brain in a model of Alzheimer\u2019s pathology","volume":"150","author":"Mittal","year":"2011","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"issue":"1","key":"10.1016\/j.biopha.2021.112117_bib136","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejpb.2008.03.009","article-title":"Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles","volume":"70","author":"Wilson","year":"2008","journal-title":"Eur. J. Pharm. Biopharm. Off. J. Arb. fur Pharm. Verfahr. e. V."},{"issue":"1","key":"10.1016\/j.biopha.2021.112117_bib137","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s40659-016-0093-4","article-title":"Effects and molecular mechanism of chitosan-coated levodopa nanoliposomes on behavior of dyskinesia rats","volume":"49","author":"Cao","year":"2016","journal-title":"Biol. Res."},{"issue":"6","key":"10.1016\/j.biopha.2021.112117_bib138","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1080\/10837450.2020.1740257","article-title":"In vitro and in vivo evaluation of levodopa-loaded nanoparticles for nose to brain delivery","volume":"25","author":"Arisoy","year":"2020","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.biopha.2021.112117_bib139","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.actbio.2020.03.021","article-title":"Self-assembled polydopamine nanoparticles improve treatment in Parkinson\u2019s disease model mice and suppress dopamine-induced dyskinesia","volume":"109","author":"Vong","year":"2020","journal-title":"Acta Biomater."},{"key":"10.1016\/j.biopha.2021.112117_bib140","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2147\/IJN.S151475","article-title":"Lactoferrin-modified rotigotine nanoparticles for enhanced nose-to-brain delivery: LESA-MS\/MS-based drug biodistribution, pharmacodynamics, and neuroprotective effects","volume":"13","author":"Yan","year":"2018","journal-title":"Int J. Nanomed."},{"key":"10.1016\/j.biopha.2021.112117_bib141","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119148","article-title":"Nose to brain delivery of rotigotine loaded chitosan nanoparticles in human SH-SY5Y neuroblastoma cells and animal model of Parkinson\u2019s disease","volume":"579","author":"Bhattamisra","year":"2020","journal-title":"Int. J. Pharm."},{"issue":"8","key":"10.1016\/j.biopha.2021.112117_bib142","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1016\/j.nano.2018.08.004","article-title":"Pharmacokinetics and pharmacodynamics of intranasally administered selegiline nanoparticles with improved brain delivery in Parkinson\u2019s disease","volume":"14","author":"Sridhar","year":"2018","journal-title":"Nanomed.: Nanotechnol., Biol., Med."},{"key":"10.1016\/j.biopha.2021.112117_bib143","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijbiomac.2017.12.056","article-title":"Pramipexole dihydrochloride loaded chitosan nanoparticles for nose to brain delivery: development, characterization and in vivo anti-Parkinson activity","volume":"109","author":"Raj","year":"2018","journal-title":"Int. J. Biol. Macromol."},{"issue":"3","key":"10.1016\/j.biopha.2021.112117_bib144","first-page":"393","article-title":"Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model","volume":"48","author":"Md","year":"2013","journal-title":"Eur. J. Pharm. Sci. Off. J. Eur. Fed. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2021.112117_bib145","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.thromres.2011.11.010","article-title":"Thrombolytic efficacy of tissue plasminogen activator-loaded echogenic liposomes in a rabbit thrombus model","volume":"130","author":"Laing","year":"2012","journal-title":"Thromb. Res."},{"key":"10.1016\/j.biopha.2021.112117_bib146","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.biomaterials.2015.12.009","article-title":"Tissue plasminogen activator followed by antioxidant-loaded nanoparticle delivery promotes activation\/mobilization of progenitor cells in infarcted rat brain","volume":"81","author":"Petro","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.biopha.2021.112117_bib147","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.05.020","article-title":"Encapsulation of tissue plasminogen activator in pH-sensitive self-assembled antioxidant nanoparticles for ischemic stroke treatment - Synergistic effect of thrombolysis and antioxidant","volume":"215","author":"Mei","year":"2019","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.biopha.2021.112117_bib148","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11095-017-2324-y","article-title":"Chitosan engineered PAMAM dendrimers as nanoconstructs for the enhanced anti-cancer potential and improved in vivo brain pharmacokinetics of temozolomide","volume":"35","author":"Sharma","year":"2018","journal-title":"Pharm. Res."},{"issue":"30","key":"10.1016\/j.biopha.2021.112117_bib149","doi-asserted-by":"crossref","first-page":"10919","DOI":"10.1039\/C7NR00305F","article-title":"A polymeric temozolomide nanocomposite against orthotopic glioblastoma xenograft: tumor-specific homing directed by nestin","volume":"9","author":"Prabhu","year":"2017","journal-title":"Nanoscale"},{"key":"10.1016\/j.biopha.2021.112117_bib150","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jconrel.2017.06.028","article-title":"Liposomal temozolomide drug delivery using convection enhanced delivery","volume":"261","author":"Nordling-David","year":"2017","journal-title":"J. Control. Release: Off. J. Control. Release Soc."},{"issue":"1","key":"10.1016\/j.biopha.2021.112117_bib151","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1038\/s41467-018-04315-4","article-title":"Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles","volume":"9","author":"Lam","year":"2018","journal-title":"Nat. Commun."},{"issue":"43","key":"10.1016\/j.biopha.2021.112117_bib152","doi-asserted-by":"crossref","first-page":"39525","DOI":"10.1021\/acsami.9b13829","article-title":"Enhanced efficacy of temozolomide loaded by a tetrahedral framework dna nanoparticle in the therapy for glioblastoma","volume":"11","author":"Fu","year":"2019","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"9","key":"10.1016\/j.biopha.2021.112117_bib153","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1158\/1535-7163.MCT-18-1250","article-title":"Encapsulation of temozolomide in a calixarene nanocapsule improves its stability and enhances its therapeutic efficacy against glioblastoma","volume":"18","author":"Renziehausen","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2021.112117_bib154","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jconrel.2019.07.015","article-title":"Codelivery of paclitaxel and temozolomide through a photopolymerizable hydrogel prevents glioblastoma recurrence after surgical resection","volume":"309","author":"Zhao","year":"2019","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"issue":"1","key":"10.1016\/j.biopha.2021.112117_bib155","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-14036-x","article-title":"Dual functionalized brain-targeting nanoinhibitors restrain temozolomide-resistant glioma via attenuating EGFR and MET signaling pathways","volume":"11","author":"Meng","year":"2020","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.biopha.2021.112117_bib156","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1021\/acs.bioconjchem.8b00220","article-title":"Nanoparticle formulation derived from carboxymethyl cellulose, polyethylene glycol, and cabazitaxel for chemotherapy delivery to the brain","volume":"29","author":"Bteich","year":"2018","journal-title":"Bioconjugate Chem."},{"issue":"5","key":"10.1016\/j.biopha.2021.112117_bib157","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1166\/jbn.2016.2215","article-title":"Lipid-core nanocapsules act as a drug shuttle through the blood brain barrier and reduce glioblastoma after intravenous or oral administration","volume":"12","author":"Rodrigues","year":"2016","journal-title":"J. Biomed. Nanotechnol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222100901X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222100901X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T08:06:08Z","timestamp":1771920368000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222100901X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":157,"alternative-id":["S075333222100901X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112117","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanotechnology-based drug delivery for central nervous system disorders","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112117","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"112117"}}